In a nutshell: While specific angiogenesis inhibitors currently do not have an established role in PCa, targeting tumor angiogenesis and tumor-associated blood vessels probably is part of established PCa therapies – especially regarding PSMA-directed approaches. Here, FOLH1 is linked to neoplasm.